Physician profile
Karin E Riepe
NPI 1093709446
$3,706.86
in general payments reported to CMS, 2019-2025
18 companies · $74.34 in 2025
The $74.34 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $759 · 2022: $617 · 2023: $1,055 · 2024: $1,203 · 2025: $74.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,331.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $796.71 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $601.68 | 2021-2024 | Airsupra |
| Neurocrine Biosciences, INC. | $499.48 | 2022-2024 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $268.81 | 2023-2024 | Austedo Xr, Uzedy |
| Amgen INC. | $220.49 | 2021-2023 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $171.40 | 2021 | |
| Abbott Laboratories | $171.07 | 2023 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $152.58 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Tempus Ai, INC | $124.38 | 2024 | |
| Glaxosmithkline, LLC. | $112.89 | 2022 | |
| Urovant Sciences INC | $112.30 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $82.03 | 2024 | Rexulti |
| Viiv Healthcare Company | $74.34 | 2025 | Apretude |
| Neurelis, INC. | $72.73 | 2023 | Valtoco |
| Mylan Specialty L.P. | $70.85 | 2024 | Yupelri |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.91 | 2021 | |
| Sanofi Pasteur INC. | $53.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin Riepe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.